{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T16:02:29Z","timestamp":1767888149563,"version":"3.49.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3287,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,9]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>In chronic hepatitis B, it is difficult to predict an early therapeutic response. We investigated the viral decline during therapy with pegylated interferon alpha-2b (PEG-IFN) with or without lamivudine in 266 HBeAg-positive chronic hepatitis B patients. In patients treated with PEG-IFN and lamivudine, a uniform biphasic viral decline pattern was found during therapy and there were no marked differences in viral load between those who lost HBeAg at the end of follow-up (response) or not. In contrast, those treated with PEG-IFN monotherapy exhibited different viral decline patterns. A delayed decline of at least two log from baseline HBV DNA after week 4 but before week 32 was associated with the highest response rate (63%). In comparison, response was 52% for patients with an early decline (week 0-4), 38% for a late decline (week 32-52), 27% for a posttreatment decline (week 52-78) and 11% for patients with no substantial decline. The HBsAg loss was 22% in the delayed decline pattern compared to 4% for those with early decline and none for other decline patterns.<\/jats:bold>\n                                 <jats:bold>\n                                    In conclusion\n                                 <\/jats:bold>\n                                 <jats:bold>, different patterns of decline in viral load during treatment with PEG-IFN monotherapy were associated with different rates of HBeAg and HBsAg loss at the end of follow-up. Since there was a considerable response, even in patients with a late or posttreatment decline pattern, prediction of response based on viral decline during the first months of therapy was difficult.<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21302","type":"journal-article","created":{"date-parts":[[2006,8,30]],"date-time":"2006-08-30T02:02:28Z","timestamp":1156903348000},"page":"721-727","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":55,"title":["Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response"],"prefix":"10.1097","volume":"44","author":[{"given":"Martijn J.","family":"ter Borg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"van Zonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Senturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulus S.","family":"Akarca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart L.","family":"Haagmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"de Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solko W.","family":"Schalm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-24-20241201","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.46.4.562","article-title":"Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.","volume":"46","author":"Schalm","year":"2000","journal-title":"Gut"},{"key":"R2-24-20241201","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199910213411702","article-title":"Lamivudine as initial treatment for chronic hepatitis B in the United States.","volume":"341","author":"Dienstag","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-24-20241201","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A oneyear trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"R4-24-20241201","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0168-8278(03)00076-X","article-title":"Lamivudine and 24 weeks of lamivudineinterferon combination therapy for hepatitis B e antigenpositive chronic hepatitis B in interferon nonresponders.","volume":"38","author":"Schiff","year":"2003","journal-title":"J Hepatol"},{"key":"R5-24-20241201","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B.","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"R6-24-20241201","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","article-title":"Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.","volume":"33","author":"Leung","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R7-24-20241201","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1053\/jhep.2000.17912","article-title":"Longterm therapy of chronic hepatitis B with lamivudine.","volume":"32","author":"Lau","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R8-24-20241201","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/jhep.2000.16665","article-title":"Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.","volume":"32","author":"Song","year":"2000","journal-title":"HEPATOLOGY"},{"issue":"Suppl 2","key":"R9-24-20241201","first-page":"17","article-title":"Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil therapy for patients with chronic hepatitis B. Abstract.","volume":"42","author":"Locarnini","year":"2005","journal-title":"J Hepatol"},{"key":"R10-24-20241201","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1056\/NEJMoa042957","article-title":"Longterm therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B.","volume":"352","author":"Hadziyannis","year":"2005","journal-title":"N Engl J Med"},{"key":"R11-24-20241201","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-119-4-199308150-00011","article-title":"Effect of alphainterferon treatment in patients with hepatitis B e antigenpositive chronic hepatitis B. A metaanalysis.","volume":"119","author":"Wong","year":"1993","journal-title":"Ann Intern Med"},{"key":"R12-24-20241201","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2893.2003.00450.x","article-title":"Peginterferon alpha2a (40 kDa): an advance in the treatment of hepatitis B e antigenpositive chronic hepatitis B.","volume":"10","author":"Cooksley","year":"2003","journal-title":"J Viral Hepat"},{"key":"R13-24-20241201","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa2b alone or in combination with lamivudine for HBeAgpositive chronic hepatitis B: a randomised trial.","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"R14-24-20241201","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa2a, lamivudine, and the combination for HBeAgpositive chronic hepatitis B.","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"R15-24-20241201","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa2a alone, lamivudine alone, and the two in combination in patients with HBeAgnegative chronic hepatitis B.","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"R16-24-20241201","first-page":"1","article-title":"2002. NIH Consens State Sci S","volume":"19","author":"NIH Consensus Statement on Management of Hepatitis","year":"2002","journal-title":"tatements"},{"issue":"Suppl 1","key":"R17-24-20241201","first-page":"S3","article-title":"EASL International Consensus Conference on Hepatitis B. 1314 September, 2002 Geneva, Switzerland. Consensus statement (long version).","volume":"39","author":"de Franchis","year":"2003","journal-title":"J Hepatol"},{"key":"R18-24-20241201","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1053\/jhep.2001.29401","article-title":"Chronic hepatitis B.","volume":"34","author":"Lok","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R19-24-20241201","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1128\/JCM.38.8.2897-2901.2000","article-title":"Development of a quantitative realtime detection assay for hepatitis B virus DNA and comparison with two commercial assays.","volume":"38","author":"Pas","year":"2000","journal-title":"J Clin Microbiol"},{"key":"R20-24-20241201","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JCM.37.1.68-73.1999","article-title":"Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group.","volume":"37","author":"Heermann","year":"1999","journal-title":"J Clin Microbiol"},{"key":"R21-24-20241201","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/hep.20831","article-title":"Hepatitis B viral kinetics: a dynamic puzzle still to be resolved.","volume":"42","author":"Neumann","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R22-24-20241201","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.20738","article-title":"A viral kinetic study using pegylated interferon alfa2b andor lamivudine in patients with chronic hepatitis BHBeAg negative.","volume":"42","author":"Sypsa","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R23-24-20241201","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1136\/gut.2004.062208","article-title":"Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peginterferon alpha2b therapy.","volume":"54","author":"Flink","year":"2005","journal-title":"Gut"},{"key":"R24-24-20241201","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1073\/pnas.93.9.4398","article-title":"Viral dynamics in hepatitis B virus infection.","volume":"93","author":"Nowak","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-24-20241201","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.510290626","article-title":"Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy.","volume":"29","author":"Tsiang","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R26-24-20241201","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1053\/jhep.2000.9143","article-title":"Combination therapy with lamivudine and famciclovir for chronic hepatitis Binfected Chinese patients: a viral dynamics study.","volume":"32","author":"Lau","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R27-24-20241201","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1053\/jhep.2001.28509","article-title":"Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed.","volume":"34","author":"Lewin","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R28-24-20241201","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1034\/j.1600-0676.2002.01579.x","article-title":"Viral dynamics in chronic hepatitis B patients during lamivudine therapy.","volume":"22","author":"Wolters","year":"2002","journal-title":"Liver"},{"key":"R29-24-20241201","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","article-title":"Longterm followup of HBeAgpositive patients treated with interferon alfa for chronic hepatitis B.","volume":"334","author":"Niederau","year":"1996","journal-title":"N Engl J Med"},{"key":"R30-24-20241201","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/jhep.2002.34294","article-title":"Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.","volume":"36","author":"Perrillo","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R31-24-20241201","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0168-8278(05)81896-3","article-title":"Ontreatment predictors of sustained biochemical and virological response in patients with HBeAgnegative chronic hepatitis B treated with peginterferon alfa2a (40KD) (PEGASYS).","volume":"42","author":"Farci","year":"2005","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21302","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200609000-00024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T12:08:57Z","timestamp":1733054937000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200609000-00024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21302","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}